Table 1 Clinical and metabolic parameters for included subjects in novel subgroups of 285 adult diabetes
From: Roles of plasma leptin and resistin in novel subgroups of type 2 diabetes driven by cluster analysis
Characteristics | MOD | SIDD | SIRD | MARD | P value |
|---|---|---|---|---|---|
N (%) | 50 (17.5) | 71 (24.8) | 48 (16.8) | 116 (40.9) | Â |
Age (years) | 39.06 ± 10.07 | 37.66 ± 11.68 | 47.56 ± 10.90 | 51.98 ± 10.05 | < 0.001 |
Male(%) | 31 (62.0) | 49 (69.0) | 35 (72.9) | 65 (56.0) | 0.135 |
BMI (kg/m2) | 30.80 ± 4.86 | 23.26 ± 3.45 | 24.70 ± 3.86 | 23.32 ± 2.94 | < 0.001 |
HbA1c | 8.40 | 11.80 | 7.50 | 7.85 | < 0.001 |
(%) | (6.90–9.90) | (10.46–13.60) | (6.43–9.78) | (6.73–9.25) | |
HOMA2-IR | 7.78 | 3.66 | 17.24 | 4.59 | < 0.001 |
(5.04–12.50) | (1.97–5.62) | (11.94–20.31) | (2.98–6.85) | ||
HOMA2-B | 178.20 | 70.70 | 461.80 | 139.50 | < 0.001 |
(92.58–266.25) | (48.90–111.40) | (350.88–576.25)) | (89.05–196.98) | ||
‘Leptin | 7.71 | 3.92 | 4.48 | 3.91 | < 0.001 |
(ng/mL) | (4.22–15.20) | (2.38–7.19) | (2.74–7.81) | (2.44–7.25) | |
Resistin | 9.22 | 8.00 | 12.05 | 6.36 | 0.014 |
(ng/mL) | (6.29–13.20) | (4.80–15.33) | (5.16–18.49) | (3.85–11.40) | |
ALT | 25.50 | 16.00 | 20.50 | 19.00 | 0.035 |
(U/L) | (15.75–50.25) | (12.25–25.75) | (13.75–29.25) | (14.00–31.00) | |
AST | 18.50 | 16.00 | 20.00 | 19.00 | 0.001 |
(U/L) | (15.00–35.50) | (12.50–21.50) | (16.75–27.25) | (17.00–26.00) | |
TC | 4.05 | 4.32 | 4.00 | 3.98 | 0.550 |
(mmol/L) | (3.46–4.78) | (3.58–4.87) | (3.38–4.76) | (3.00–4.83) | |
BUN | 5.45 | 6.00 | 6.44 | 5.80 | 0.101 |
(mmol/L) | (4.38–7.16) | (4.70–7.68) | (5.16–8.20) | (4.60–7.00) |  |
SCr | 69.00 | 67.00 | 95.00 | 70.00 | < 0.001 |
(μmol/L) | (55.50–83.00) | (50.00–77.00) | (64.75–132.75) | (56.00–88.00) | |
eGFR | 102.80 | 109.60 | 76.60 | 92.00 | < 0.001 |
(mL/min/1.73m2) | (87.30–115.05) | (97.03–122.23) | (46.90–99.70) | (75.30–102.40) |